The AIM-HIGH trial showed significant DFS improvement in high-risk stage 1a to 2a nonsquamous NSCLC patients receiving adjuvant chemotherapy. At 24 months, 96% of chemotherapy patients were alive ...
Ibtrozi is a medicine called a kinase inhibitor that is used to treat a certain type of lung cancer called non-small-cell lung cancer (NSCLC) that is caused by an abnormal ROS1 gene. NSCLC is the most ...
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical ...
Please provide your email address to receive an email when new articles are posted on . Surgery and stereotactic ablative radiotherapy conferred comparable 10-year survival among patients with ...
Dr Jonathan Goldman of the University of California, Los Angeles, highlights key abstracts in early-stage NSCLC from ASCO 2025. Dr Goldman begins with updated results from CheckMate 816, comparing ...
In older cancer patients, receiving federal housing assistance is associated with earlier-stage diagnosis of breast cancer, colorectal cancer, and NSCLC.
Lung cancer is the second most common cancer in both men and women in the United States and the leading cause of cancer-related deaths - more than colon, breast and prostate cancers combined. Many ...
An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway Results from the IDeate-Lung01 ...
Lung cancer is the leading cause of cancer deaths in the U.S., according to the American Cancer Society. For people battling a certain type of lung cancer, there’s good news.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback